Aandeel OUTLOOK THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen OUTLOOK THERAPEUTICS, INC. Nasdaq

Aandelen

US69012T1079

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
European Biosimilar Regulatory Update
Corporate Presentation: June 2024
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD
CoStar Group has room for expansion
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
Outlook Therapeutics® to Present at the Retina World Congress 2024
Outlook Therapeutics, Inc. Announces Change in Headquarters Address
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers OTLK
  4. Koers
  5. Nieuws OUTLOOK THERAPEUTICS, INC.
  6. Andere talen